Article

Lymphoma Drug Adcetris Tested in Newly Diagnosed Patients

With the approval of Adcetris (brentuximab vedotin) for relapsed Hodgkin lymphoma, researchers are now examining whether the drug will help newly diagnosed patients.

With the August approval of Adcetris (brentuximab vedotin) for Hodgkin lymphoma patients who have relapsed after stem cell transplantation or two lines of chemotherapy, researchers are now examining whether the drug will help newly diagnosed patients. Adcetris, an antibody-drug conjugate, combines a chemotherapy agent with an antibody that targets the CD30 receptor found on lymphoma cells.

Although early, results of a phase 1 study show Adcetris’ potential benefit with standard chemotherapy. The purpose of the trial was to determine the best dosing strategy and toxicity, not efficacy. Yet the first 15 of 44 patients evaluated in the trial had complete remissions. Side effects included neutropenia and anemia. A phase 3 study is in the works.

Related Videos
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of a woman with a brown hair tied into a bun.